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Abstract
In the present case, thermal ablation of the Barrett’s remainder by argon plasma coagulation (APC) is shown in a patient
recently cured of early Barrett’s cancer by endoscopic resection. Ablation is carried out in order to reduce the risk of
metachronous neoplasia in the residual nonneoplastic Barrett’s esophagus.
APC is applied dynamically in longitudinal and circumferential stripes, and a wattage of 50 is used. In this patient, the
Barrett’s segment is completely ablated in one session. This article is part of an expert video encyclopedia.
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Video available to view or download at doi:
Materials
• APC (VIO APC 300D with APC 2; ERBE Elektromedizin
GmbH, Tu¨bingen, Germany).
• Flexible front-ﬁre APC probe (ERBE Elektromedizin
GmbH, Tu¨bingen, Germany).
• Pulsed APC; effect 2; VIO APC 200 (ERBE Elektromedizin
GmbH, Tu¨bingen, Germany).
Background and Endoscopic Procedure
Argon plasma coagulation (APC) is a widely established
method in gastrointestinal endoscopy.
The ﬁrst video shows the theoretical background of APC
and the second video shows a case of APC ablation in Barrett’s
esophagus (BE).
When using APC during endoscopy, an ablation probe is
introduced via the working channel of the endoscope, and
thermal energy is transferred to the target tissue via ionized
argon gas without the need of direct contact of the APC probe
to the tissue.
APC has been shown to be effective and safe especially in
various gastrointestinal bleeding disorders and BE.1
In BE, thermal ablation is mainly carried out after suc-
cessful endoscopic treatment of early Barrett’s neoplasia in
order to reduce the risk of metachronous neoplasia in the
nonneoplastic Barrett’s remainder.2,3 In contrast, ablation of
primarily nonneoplastic BE is not indicated because of a very
low risk of malignant transformation.
In the present case, thermal ablation of the Barrett’s re-
mainder by APC is shown in a patient recently cured from
early Barrett’s cancer by endoscopic resection (ER).
APC is applied dynamically in longitudinal and circum-
ferential stripes, and a wattage of 50 is used (pulsed APC,
effect 2; VIO APC 300D with APC 2). During one ablation
session, the Barrett’s segment can be completely ablated in the
present case.
There are general recommendations that can be given for
endoscopists who use APC ablation for BE. First, in order to
avoid painful distension of the stomach or other abdominal
organs, intermittent suction of the argon gas previously in-
ﬂated should be carried out during an APC procedure, or at
least at the end of any APC procedure in the gastrointestinal
tract. Second, coagulated and dehydrated tissue may get stuck
on the tip of the APC probe. To avoid coagulation of the APC
probe, intermittent cleaning of the tip is recommended. Third,
direct contact of the tip of the APC probe with the target tissue
should be avoided whenever possible in order to keep the risk
of gastrointestinal (GI) wall perforation as low as possible.
In general, APC is considered a contact-free ablation
method. APC of the target tissue can be carried out using a
distance of 1–5 mm, depending on the power setting used: the
higher the power setting chosen, the larger can be the distance
to the target tissue.
Several trials have been able to show that it is in general
feasible and safe to eradicate BE by means of APC. Neverthe-
less, incomplete eradication may occur.4,5 In the largest trial
reported on this issue so far, the complete BE eradication rate
was 77%.1
APC, as any other ablation method, for example, also the
widely used method of radiofrequency ablation (RFA), should
not be used in BE that still shows neoplastic changes, in-
cluding macroscopic changes such as nodularities or ulcer-
ations, or histologically proven neoplasia in ﬂat BE. In these
cases, residual malignancy should primarily be ruled out by
biopsy or ER, depending on the macroscopic appearance, as
only through this can a true tissue diagnosis be obtained.
According to the recently published consensus statements
for management of Barrett’s dysplasia,6 RFA was described as
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the currently best available ablation technique for eradi-
cation of residual Barrett’s mucosa after focal ER. Other
ablation techniques mentioned in these statements were
APC, as used in the present case, and cryotherapy.6 However,
it has to be pointed out that up to now, no randomized
trial exists comparing RFA to APC or cryotherapy in
nonneoplastic BE. Therefore, the value of the various
methods of thermal ablation has not yet been deﬁnitely
clariﬁed.
It can be assumed that for long BE segments, the
balloon-based method of RFA may be quicker than APC
because fewer ablation sessions may be required for
complete ablation. However, APC may be useful especially
for the ablation of small Barrett’s remainders, for example,
in the area of the esophagogastric junction, or for islands
of residual BE, as it is quick and easy to use and
relatively cheap.
It is still under discussion whether APC may lead to a
higher rate of buried glands in comparison with RFA.
However, up to now, no randomized trial has been published
on this issue. In the literature, buried glands have been
reported in up to 40% of patients with BE treated by
APC.4,5 This relatively high rate of buried glands may
have derived from an inhomogenous depth of tissue injury
as a result of APC. It has therefore to be pointed out that
APC has to be carried out meticulously in order to ablate
BE homogenously. However, long-term results of ER plus
APC for eradication of Barrett’s neoplasia and ablation
of the BE remainder have been reported to be excellent.3
Therefore, APC still plays an important role in the manage-
ment of BE.
Key Learning Points/Tips and Tricks
• APC should be used dynamically in order to avoid deep GI
wall damage; do not stay too long in one place (at best
1–2 s).
• APC is applied longitudinally or circumferentially.
• For Barrett’s ablation, a mean wattage of 40–50 (pulsed
APC, effect 2; VIO 300D with APC 2) should be chosen in
order to keep the rate of complications low (especially
strictures) and to achieve an adequate ablation success.
• The tip of the APC probe (approximately 1 cm in length)
should be visible during ablation in order to avoid damage
to the endoscope.
• Direct contact of the tip of the APC probe to the target
tissue should be avoided whenever possible during appli-
cation in the GI tract in order to avoid deep thermal
damage to the GI wall. In general, APC can be used as a
contact-free ablation method. In clinical practice, the dis-
tance between the tip of the probe and the target tissue is at
best 1–5 mm, depending on the power setting used.
• To avoid painful distension of the stomach or other ab-
dominal organs, intermittent suction of the argon gas
should be carried out during any APC procedure.
• Coagulated and dehydrated tissue may get stuck at the tip
of the APC probe during an ablation procedure. It is rec-
ommended to clean the tip of the probe intermittently in
order to avoid coagulation effects at the tip of the probe.
Scripted Voiceover
Video 1
Time
(min:sec)
Voiceover text
00:00–00:05 This video shows the physical principle of argon
plasma coagulation.
00:06–00:13 The argon plasma coagulation (APC) system
consists of a gas source, for example argon gas, a
high-frequency generator, and an applicator.
00:14–00:26 The high-frequency electrode of the applicator is
surrounded by argon gas. The high-frequency
current ionizes the argon gas, and a plasma ﬁeld is
created between the probe tip and the tissue
surface.
00:27–00:33 This allows the current to ﬂow to the tissue without
contact.
00:34–00:39 The thermal effect causes a dehydration of the tissue
that is decreasing its contactivity.
00:40–00:52 The ﬂow lines diverge automatically to hemorrhagic,
electrically more conductive areas. This creates a
self-limiting, uniform penetration depth.
00:53–01:04 First, a zone of desiccation forms at the tissue
surface. Below it, a zone of coagulation, and then
of devitalization, is created.
01:05–01:08 There is no vaporization as with a laser.
01:09–01:12 Desiccation causes an immediate shrinkage of the
tissue.
01:13–01:17 There is very little char build up in the tissue since
argon is an inert gas.
Video 2
Time
(min:sec)
Voiceover text
00:00–00:17 This 70-year-old patient recently underwent
endoscopic resection for early Barrett’s cancer.
Scarring and residual Barrett’s mucosa can be
seen mainly at the gastroesophageal
junction.
00:18–00:25 Thermal ablation of residual Barrett’s is carried out
using argon plasma coagulation (APC).
00:26–00:42 After a ﬂexible APC probe has been introduced via
the working channel of the endoscope, the
Barrett’s mucosa is ablated dynamically using a
wattage of 50.
00:43–00:49 Finally, tiny islands of Barrett’s mucosa are ablated in
the tubular esophagus.
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